Mode
Text Size
Log in / Sign up
Phase 4 N=24 Randomized Single-blind Supportive Care

Postoperative Dexamethasone on Post-Cesarean Pain

Post-Cesarean Pain · Cesarean Section Complications

Enrolled (actual)
24
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Mean Pain Score — 4.1; 4.2; 5.1; 5.2 score on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Dexamethasone (Drug); placebo (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Yale University
Primary completion
Apr 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Pain Score
4.1; 4.2; 5.1; 5.2; 4.6; 4.5
SECONDARY
Change of Morphine Use
32.3; 34.4; 38.3; 44.5; 14.3; 20.6

Summary

Investigating if giving post-operative dexamethasone to patients with a history of opioid use disorder on medication assisted treatment during pregnancy improves their pain scores and decreases their opioid use after cesarean section.

Eligibility Criteria

Inclusion Criteria

  • English-speaking,
  • History of opioid use disorder with current use of MAT during pregnancy,
  • Scheduled for cesarean delivery for their current pregnancy for any indication [examples of elective c-section (decision made for c-section to be performed prior to onset of labor): fetal malpresentation, suspected macrosomia, prior c-section, abnormal placentation, patient preference],
  • Negative toxicology screen upon admission to the hospital for their cesarean section, no prior administration of betamethasone for fetal lung maturity within 24h of their scheduled cesarean delivery

Exclusion Criteria

  • non-english speaking,
  • screen positive for illicit substance(s) on their admission toxicology screen,
  • require general anesthesia for their cesarean section due to maternal/fetal indication for non-anticipated urgency (thus no longer 'elective') or failure of adequate intra- operative pain control with spinal anesthesia,
  • medical history including known cardiovascular disease, heart failure, uncontrolled hypertension, uncontrolled gestational diabetes or uncontrolled pregestational diabetes, active GI bleed or untreated peptic ulcer,
  • untreated infectious diseases including tuberculosis, systemic candida
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04067609). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search